Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting

Research output: Research - peer-reviewJournal article

Standard

Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. / Tietze, Anna; Choi, Changho; Mickey, Bruce; Maher, Elizabeth A; Parm Ulhøi, Benedicte; Sangill, Ryan; Lassen-Ramshad, Yasmin; Lukacova, Slavka; Østergaard, Leif; von Oettingen, Gorm.

In: Journal of Neurosurgery: Spine, 01.02.2018, p. 1-8.

Research output: Research - peer-reviewJournal article

Harvard

Tietze, A, Choi, C, Mickey, B, Maher, EA, Parm Ulhøi, B, Sangill, R, Lassen-Ramshad, Y, Lukacova, S, Østergaard, L & von Oettingen, G 2018, 'Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting' Journal of Neurosurgery: Spine, pp. 1-8. DOI: 10.3171/2016.10.JNS161793

APA

Tietze, A., Choi, C., Mickey, B., Maher, E. A., Parm Ulhøi, B., Sangill, R., ... von Oettingen, G. (2018). Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Journal of Neurosurgery: Spine, 1-8. DOI: 10.3171/2016.10.JNS161793

CBE

Tietze A, Choi C, Mickey B, Maher EA, Parm Ulhøi B, Sangill R, Lassen-Ramshad Y, Lukacova S, Østergaard L, von Oettingen G. 2018. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Journal of Neurosurgery: Spine. 1-8. Available from: 10.3171/2016.10.JNS161793

MLA

Vancouver

Author

Tietze, Anna ; Choi, Changho ; Mickey, Bruce ; Maher, Elizabeth A ; Parm Ulhøi, Benedicte ; Sangill, Ryan ; Lassen-Ramshad, Yasmin ; Lukacova, Slavka ; Østergaard, Leif ; von Oettingen, Gorm. / Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. In: Journal of Neurosurgery: Spine. 2018 ; pp. 1-8

Bibtex

@article{c569317031e74fb1bde921f10f83f21b,
title = "Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting",
abstract = "OBJECTIVE Mutations in the isocitrate dehydrogenase (IDH) genes are of proven diagnostic and prognostic significance for cerebral gliomas. The objective of this study was to evaluate the clinical feasibility of using a recently described method for determining IDH mutation status by using magnetic resonance spectroscopy (MRS) to detect the presence of 2-hydroxyglutarate (2HG), the metabolic product of the mutant IDH enzyme. METHODS By extending imaging time by 6 minutes, the authors were able to include a point-resolved spectroscopy (PRESS) MRS sequence in their routine glioma imaging protocol. In 30 of 35 patients for whom this revised protocol was used the lesions were subsequently diagnosed histologically as gliomas. Of the remaining 5 patients, 1 had a gangliocytoma, 1 had a primary CNS lymphoma, and 3 had nonneoplastic lesions. Immunohistochemistry and/or polymerase chain reaction were used to detect the presence of IDH mutations in the glioma tissue resected. RESULTS In vivo MRS for 2HG correctly identified the IDH mutational status in 88.6% of patients. The sensitivity and specificity was 89.5% and 81.3%, respectively, when using 2 mM 2HG as threshold to discriminate IDH-mutated from wildtype tumors. Two glioblastomas that had elevated 2HG levels did not have detectable IDH mutations, and in 2 IDH-mutated gliomas 2HG was not reliably detectable. CONCLUSIONS The noninvasive determination of the IDH mutation status of a presumed glioma by means of MRS may be incorporated into a routine diagnostic imaging protocol and can be used to obtain additional information for patient care.",
keywords = "Journal Article",
author = "Anna Tietze and Changho Choi and Bruce Mickey and Maher, {Elizabeth A} and {Parm Ulhøi}, Benedicte and Ryan Sangill and Yasmin Lassen-Ramshad and Slavka Lukacova and Leif Østergaard and {von Oettingen}, Gorm",
year = "2018",
month = "2",
doi = "10.3171/2016.10.JNS161793",
pages = "1--8",
journal = "Journal of Neurosurgery: Spine",
issn = "1547-5654",
publisher = "American Association of Neurological Surgeons",

}

RIS

TY - JOUR

T1 - Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting

AU - Tietze,Anna

AU - Choi,Changho

AU - Mickey,Bruce

AU - Maher,Elizabeth A

AU - Parm Ulhøi,Benedicte

AU - Sangill,Ryan

AU - Lassen-Ramshad,Yasmin

AU - Lukacova,Slavka

AU - Østergaard,Leif

AU - von Oettingen,Gorm

PY - 2018/2/1

Y1 - 2018/2/1

N2 - OBJECTIVE Mutations in the isocitrate dehydrogenase (IDH) genes are of proven diagnostic and prognostic significance for cerebral gliomas. The objective of this study was to evaluate the clinical feasibility of using a recently described method for determining IDH mutation status by using magnetic resonance spectroscopy (MRS) to detect the presence of 2-hydroxyglutarate (2HG), the metabolic product of the mutant IDH enzyme. METHODS By extending imaging time by 6 minutes, the authors were able to include a point-resolved spectroscopy (PRESS) MRS sequence in their routine glioma imaging protocol. In 30 of 35 patients for whom this revised protocol was used the lesions were subsequently diagnosed histologically as gliomas. Of the remaining 5 patients, 1 had a gangliocytoma, 1 had a primary CNS lymphoma, and 3 had nonneoplastic lesions. Immunohistochemistry and/or polymerase chain reaction were used to detect the presence of IDH mutations in the glioma tissue resected. RESULTS In vivo MRS for 2HG correctly identified the IDH mutational status in 88.6% of patients. The sensitivity and specificity was 89.5% and 81.3%, respectively, when using 2 mM 2HG as threshold to discriminate IDH-mutated from wildtype tumors. Two glioblastomas that had elevated 2HG levels did not have detectable IDH mutations, and in 2 IDH-mutated gliomas 2HG was not reliably detectable. CONCLUSIONS The noninvasive determination of the IDH mutation status of a presumed glioma by means of MRS may be incorporated into a routine diagnostic imaging protocol and can be used to obtain additional information for patient care.

AB - OBJECTIVE Mutations in the isocitrate dehydrogenase (IDH) genes are of proven diagnostic and prognostic significance for cerebral gliomas. The objective of this study was to evaluate the clinical feasibility of using a recently described method for determining IDH mutation status by using magnetic resonance spectroscopy (MRS) to detect the presence of 2-hydroxyglutarate (2HG), the metabolic product of the mutant IDH enzyme. METHODS By extending imaging time by 6 minutes, the authors were able to include a point-resolved spectroscopy (PRESS) MRS sequence in their routine glioma imaging protocol. In 30 of 35 patients for whom this revised protocol was used the lesions were subsequently diagnosed histologically as gliomas. Of the remaining 5 patients, 1 had a gangliocytoma, 1 had a primary CNS lymphoma, and 3 had nonneoplastic lesions. Immunohistochemistry and/or polymerase chain reaction were used to detect the presence of IDH mutations in the glioma tissue resected. RESULTS In vivo MRS for 2HG correctly identified the IDH mutational status in 88.6% of patients. The sensitivity and specificity was 89.5% and 81.3%, respectively, when using 2 mM 2HG as threshold to discriminate IDH-mutated from wildtype tumors. Two glioblastomas that had elevated 2HG levels did not have detectable IDH mutations, and in 2 IDH-mutated gliomas 2HG was not reliably detectable. CONCLUSIONS The noninvasive determination of the IDH mutation status of a presumed glioma by means of MRS may be incorporated into a routine diagnostic imaging protocol and can be used to obtain additional information for patient care.

KW - Journal Article

U2 - 10.3171/2016.10.JNS161793

DO - 10.3171/2016.10.JNS161793

M3 - Journal article

SP - 1

EP - 8

JO - Journal of Neurosurgery: Spine

T2 - Journal of Neurosurgery: Spine

JF - Journal of Neurosurgery: Spine

SN - 1547-5654

ER -